28.07
Hims Hers Health Inc stock is traded at $28.07, with a volume of 10.98M.
It is down -4.46% in the last 24 hours and up +0.25% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$29.38
Open:
$29.51
24h Volume:
10.98M
Relative Volume:
0.99
Market Cap:
$6.55B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
53.76
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
-9.22%
1M Performance:
+0.25%
6M Performance:
+4.00%
1Y Performance:
-52.54%
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HIMS
Hims Hers Health Inc
|
28.07 | 6.55B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-26 | Resumed | JP Morgan | Neutral |
| May-12-26 | Reiterated | Needham | Buy |
| Apr-24-26 | Initiated | JP Morgan | Overweight |
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Hims & Hers Health Inc (HIMS) Stock Down 4.5% -- Now Undervalued? GF Score: 75/100 - GuruFocus
ROSEN, LEADING INVESTOR COUNSEL, Encourages Millrose Properties, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionMRP - GlobeNewswire Inc.
HIMS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
What Does Hims & Hers Health (HIMS) Expansion Into The UK And Australia Mean? - Yahoo Finance
Hims & Hers Health (HIMS) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline - PR Newswire
How Is Hims & Hers Health, Inc. (NYSE:HIMS) Reshaping Its Business? - Kalkine Media
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald
Kaplan Fox & Kilsheimer LLP Encourages Hims & Hers Health, Inc - The National Law Review
Hims & Hers Health rises as HHS moves ahead with plan for compounding peptides - Seeking Alpha
US FDA takes step to change peptide compounding policy - Reuters
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Our Commitment to Independent, Clinician-Led Care - Hims & Hers Newsroom
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP AnnouncesHIMS - GlobeNewswire Inc.
Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action - GlobeNewswire Inc.
HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitNovember 2, 2026 Deadline - PR Newswire
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Zacks Investment Research
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
Hims & Hers Expands Australian Women's Health Platform With Hers - Zacks Investment Research
Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately - PR Newswire
Innovating for Her - Hims & Hers Newsroom
HIMS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
PZZA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Papa John’s International, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionPZZA - GlobeNewswire Inc.
Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately - GlobeNewswire Inc.
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Hims & Hers Health: The Bullish Case Is Hard To Forecast, But It Is Asymmetrical - Seeking Alpha
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire
Should You Trim Or Add To Your Hims & Hers Position Now? - Trefis
Kaplan Fox Notifies Hims & Hers Health, Inc. (NYSE: HIMS) Investo - The National Law Review
Hims & Hers Launches Hers Women’s-Health Platform in Australia - www.tokenpost.com
Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026 - HIMS investor relations
Hims & Hers (HIMS) Launches Hers Brand in Australia, Expanding W - GuruFocus
Hers Launches in Australia - Hims & Hers Newsroom
Hers Launches in Australia, Built to Care for the Whole Woman - Business Wire
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
Hims & Hers Health, Inc. (HIMS) Stock Forecasts - Yahoo Finance
Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud - GlobeNewswire
Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud Class Action After FTC Lawsuit Reveal Drives Stock Sharply LowerHBSS - GlobeNewswire Inc.
Hims & Hers Health climbs 10% amid recent volatile trading (HIMS:NYSE) - Seeking Alpha
Hims & Hers Health Jumps 7.3% Amid Sector-Wide Rally - AlphaStreet
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - WBOC TV
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - Yahoo Finance
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now - The Globe and Mail
Hims & Hers Health Shares Slide as Investors Weigh Accounting Leadership Change and Ongoing Margin Questions - Quiver Quantitative
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hims Hers Health Inc Stock (HIMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boughton Soleil | Officer |
Oct 14 '26 |
Proposed Sale |
29.06 |
3,461 |
100,577 |
0 |
| Okupe Oluyemi | Chief Financial Officer |
Oct 01 '26 |
Sale |
29.70 |
2,000 |
59,400 |
234,527 |
| Okupe Oluyemi | Officer |
Oct 01 '26 |
Proposed Sale |
29.70 |
2,000 |
59,400 |
0 |
| Boughton Soleil | Chief Legal Officer |
Sep 30 '26 |
Sale |
29.17 |
3,461 |
100,957 |
300,809 |
| Boughton Soleil | Officer |
Sep 30 '26 |
Proposed Sale |
29.17 |
3,461 |
100,957 |
0 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 22 '26 |
Option Exercise |
5.01 |
14,000 |
70,140 |
265,804 |
| Okupe Oluyemi | Officer |
Sep 22 '26 |
Proposed Sale |
29.95 |
29,277 |
876,846 |
0 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 22 '26 |
Sale |
29.95 |
29,277 |
876,846 |
236,527 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 17 '26 |
Sale |
28.82 |
12,313 |
354,861 |
251,804 |
| Okupe Oluyemi | Officer |
Sep 17 '26 |
Proposed Sale |
28.82 |
12,313 |
354,861 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):